期刊
MICROBIAL DRUG RESISTANCE
卷 19, 期 4, 页码 295-297出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/mdr.2012.0238
关键词
-
资金
- American Proficiency Institute (API)
- Anacor
- Astellas
- AstraZeneca
- Bayer
- Cempra
- Cerexa
- Contrafect
- Cubist
- Daiichi
- Dipexium
- Enanta
- Furiex
- GlaxoSmithKline
- Johnson & Johnson (Ortho McNeil)
- LegoChem Biosciences, Inc.
- Meiji Seika Kaisha
- Merck
- Nabriva
- Novartis
- Pfizer (Wyeth)
- Rempex
- Rib-X Pharmaceuticals
- Seachaid
- Shionogi
- Medicines Co.
- Theravance
- ThermoFisher
During 2007 to 2010, 23 carbapenem-resistant Enterobacteriaceae strains were recovered in two hospitals in Texas among three institutions surveyed. Eighteen (2.0% overall) strains carried bla(KPC-2) and were collected in 2008 (3/150; 2.0%) and 2010 (15/289; 5.1%). Clonality was noted within hospitals and ten isolates belonged to ST258. All strains carried bla(KPC-2) on plasmids and 14 had this gene embedded in Tn4401a. Tn3 transposase was detected upstream of bla(KPC-2) in two isolates and another strain had two adjacent copies of bla(KPC). Surveillance in prior years shows sporadic detection of KPC-producers in Texas, however, a recent increase in carbapenem-resistant Enterobacteriaceae in this state was due to the spread of KPC-producing Klebsiella pneumoniae, including isolates from ST258.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据